Jazz Pharmaceuticals
JAZZ
462 hedge funds and large institutions have $8.87B invested in Jazz Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 76 funds opening new positions, 150 increasing their positions, 146 reducing their positions, and 59 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 3 → 9 (+6)
29% more first-time investments, than exits
New positions opened: 76 | Existing positions closed: 59
23% more call options, than puts
Call options by funds: $58.7M | Put options by funds: $47.8M
20% more capital invested
Capital invested by funds: $7.37B → $8.87B (+$1.5B)
2% more funds holding
Funds holding: 454 → 462 (+8)
3% more repeat investments, than reductions
Existing positions increased: 150 | Existing positions reduced: 146
1.86% less ownership
Funds ownership: 94.03% → 92.17% (-1.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$74.9M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$64.4M |
| 3 |
Millennium Management
New York
|
+$53.2M |
| 4 |
SC
Samlyn Capital
New York
|
+$41.2M |
| 5 |
ACM
Atika Capital Management
New York
|
+$28.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Boston Partners
Boston,
Massachusetts
|
-$75.7M |
| 2 |
Norges Bank
Oslo,
Norway
|
-$71.6M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$70.8M |
| 4 |
AC
Armistice Capital
New York
|
-$58.9M |
| 5 |
HM
HealthCor Management
New York
|
-$49.3M |
JAZZ Hedge Fund Activity: Q1 2022 in Review
462 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q1 2022, worth a combined $8.87B — up 20% from $7.37B a quarter earlier.
Buyers outnumbered sellers: 76 funds opened new JAZZ positions and 59 closed out — a net gain of 17 holders — while 150 added to existing stakes and 146 trimmed.
The largest buyer was PFM Health Sciences, opening a new position worth an estimated $74.9M. The largest seller was Boston Partners, cutting an estimated $75.7M.
- 462 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q1 2022, up from 454 in Q4 2021.
- Funds reported $8.87B of Jazz Pharmaceuticals stock for Q1 2022, up 20% quarter-over-quarter.
- 76 funds opened new Jazz Pharmaceuticals positions in Q1 2022 and 59 closed out, a net change of +17 holders.
- The largest Jazz Pharmaceuticals buyer in Q1 2022 was PFM Health Sciences, an estimated $74.9M added.
- The largest Jazz Pharmaceuticals seller in Q1 2022 was Boston Partners, an estimated $75.7M sold.
Based on aggregated 13F filings for Q1 2022.